Want to see ALT full AI Analyst Report?
Total Valuation
Altimmune has a market cap or net worth of $583.42M. The enterprise value is $273.45.
Market Cap$583.42M
Enterprise Value$273.45
Share Statistics
Altimmune has 194,474,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding194,474,150
Owned by Insiders0.41%
Owned by Institutions1.00%
Financial Efficiency
Altimmune’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -35.36%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-35.36%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee719.30
Profits Per Employee-1.55M
Employee Count57
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Altimmune is ―. Altimmune’s PEG ratio is 0.14.
PE Ratio―
PS Ratio7757.46
PB Ratio1.41
Price to Fair Value1.41
Price to FCF-4.71
Price to Operating Cash Flow-7.10
PEG Ratio0.14
Income Statement
In the last 12 months, Altimmune had revenue of 41.00K and earned -88.09M in profits. Earnings per share was -1.00.
Revenue41.00K
Gross Profit41.00K
Operating Income-94.49M
Pretax Income-88.77M
Net Income-88.09M
EBITDA-87.03M
Earnings Per Share (EPS)-1.00
Cash Flow
In the last 12 months, operating cash flow was -76.51M and capital expenditures -54.00K, giving a free cash flow of -76.56M billion.
Operating Cash Flow-76.51M
Free Cash Flow-76.56M
Free Cash Flow per Share-0.39
Dividends & Yields
Altimmune pays an annual dividend of $873, resulting in a dividend yield of ―
Dividend Per Share$873
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.60
52-Week Price Change-21.66%
50-Day Moving Average2.90
200-Day Moving Average3.73
Relative Strength Index (RSI)48.29
Average Volume (3m)4.02M
Important Dates
Altimmune upcoming earnings date is Nov 10, 2026, TBA (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Altimmune as a current ratio of 18.55, with Debt / Equity ratio of 0.00%
Current Ratio18.55
Quick Ratio18.55
Debt to Market Cap0.11
Net Debt to EBITDA0.09
Interest Coverage Ratio-57.76
Taxes
In the past 12 months, Altimmune has paid -681.00K in taxes.
Income Tax-681.00K
Effective Tax Rate<0.01
Enterprise Valuation
Altimmune EV to EBITDA ratio is -3.56, with an EV/FCF ratio of -4.59.
EV to Sales7.56K
EV to EBITDA-3.56
EV to Free Cash Flow-4.59
EV to Operating Cash Flow-4.59
Balance Sheet
Altimmune has $326.28M in cash and marketable securities with $0.00 in debt, giving a net cash position of $326.28M billion.
Cash & Marketable Securities$326.28M
Total Debt$0.00
Net Cash$326.28M
Net Cash Per Share$1.68
Tangible Book Value Per Share$2.55
Margins
Gross margin is -48232.26%, with operating margin of -230460.98%, and net profit margin of -214860.98%.
Gross Margin-48232.26%
Operating Margin-230460.98%
Pretax Margin-216521.95%
Net Profit Margin-214860.98%
EBITDA Margin-212258.54%
EBIT Margin-212531.71%
Analyst Forecast
The average price target for Altimmune is $15.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.25
Price Target Upside450.54% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast55.00%
EPS Growth Forecast33.01%